Mafalda Oliveira

37PUBLICATIONS
331CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Jul 13, 2026
Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

|May 19, 2026
Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial.

|Feb 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Tomás Pascual, Maria Vidal, Juan M Cejalvo

|Feb 03, 2026
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Rosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum

|Jan 22, 2026
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Dec 22, 2025
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01).

Chiara Biagioni, Danai Fimereli, Alexandre Irrthum

Pageof 7

Frequent Collaborators

15 joint publications

Cristina Saura

12 joint publications

Aleix Prat

10 joint publications

Tomás Pascual

10 joint publications

Paolo Nuciforo